RNA m6A methylation regulators in endometrial cancer (Review)
- Authors:
- Siyi Shen
- Jialu Guo
- Nengyuan Lv
- Qianying Chen
- Jinyi Tong
-
Affiliations: Department of the Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China - Published online on: November 1, 2022 https://doi.org/10.3892/ijo.2022.5445
- Article Number: 155
-
Copyright: © Shen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME and Singh N: Endometrial cancer. Lancet. 399:1412–1428. 2022. View Article : Google Scholar : PubMed/NCBI | |
MacKay HJ, Freixinos VR and Fleming GF: Therapeutic targets and opportunities in endometrial cancer: Update on endocrine therapy and nonimmunotherapy targeted options. Am Soc Clin Oncol Educ Book. 40:1–11. 2020.PubMed/NCBI | |
Yang J, Chen J, Fei X, Wang X and Wang K: N6-methyladenine RNA modification and cancer. Oncol Lett. 20:1504–1512. 2020. View Article : Google Scholar : PubMed/NCBI | |
Zhou Z, Lv J, Yu H, Han J, Yang X, Feng D, Wu Q, Yuan B, Lu Q and Yang H: Mechanism of RNA modification N6-methyladenosine in human cancer. Mol Cancer. 19:1042020. View Article : Google Scholar : PubMed/NCBI | |
Yang G, Sun Z and Zhang N: Reshaping the role of m6A modification in cancer transcriptome: A review. Cancer Cell Int. 20:3532020. View Article : Google Scholar : PubMed/NCBI | |
Han X, Wang M, Zhao YL, Yang Y and Yang YG: RNA methylations in human cancers. Semin Cancer Biol. 75:97–115. 2021. View Article : Google Scholar | |
Shen S, Zhang R, Jiang Y, Li Y, Lin L, Liu Z, Zhao Y, Shen H, Hu Z, Wei Y and Chen F: Comprehensive analyses of m6A regulators and interactive coding and non-coding RNAs across 32 cancer types. Mol Cancer. 20:672021. View Article : Google Scholar : PubMed/NCBI | |
Yu AM, Jian C, Yu AH and Tu MJ: RNA therapy: Are we using the right molecules? Pharmacol Ther. 196:91–104. 2019. View Article : Google Scholar : | |
Arend RC, Jones BA, Martinez A and Goodfellow P: Endometrial cancer: Molecular markers and management of advanced stage disease. Gynecol Oncol. 150:569–580. 2018. View Article : Google Scholar : PubMed/NCBI | |
Gu B, Shang X, Yan M, Li X, Wang W, Wang Q and Zhang C: Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol. 161:573–580. 2021. View Article : Google Scholar : PubMed/NCBI | |
Ryan NAJ, Glaire MA, Blake D, Cabrera-Dandy M, Evans DG and Crosbie EJ: The proportion of endometrial cancers associated with Lynch syndrome: A systematic review of the literature and meta-analysis. Genet Med. 21:2167–2180. 2019. View Article : Google Scholar : PubMed/NCBI | |
Onstad MA, Schmandt RE and Lu KH: Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 34:4225–4230. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hecht JL and Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 24:4783–4791. 2006. View Article : Google Scholar : PubMed/NCBI | |
Bansal N, Yendluri V and Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 16:8–13. 2009. View Article : Google Scholar | |
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K and Veneris JL: Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 69:258–279. 2019.PubMed/NCBI | |
León-Castillo A, Gilvazquez E, Nout R, Smit VT, McAlpine JN, McConechy M, Kommoss S, Brucker SY, Carlson JW, Epstein E, et al: Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas. J Pathol. 250:312–322. 2020. View Article : Google Scholar | |
Bell DW and Ellenson LH: Molecular genetics of endometrial carcinoma. Annu Rev Pathol. 14:339–367. 2019. View Article : Google Scholar | |
Wang M and Hui P: A timely update of immunohistochemistry and molecular classification in the diagnosis and risk assessment of endometrial carcinomas. Arch Pathol Lab Med. 145:1367–1378. 2021. View Article : Google Scholar : PubMed/NCBI | |
Cancer Genome Atlas Research Network; Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, et al: Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI | |
Murali R, Soslow RA and Weigelt B: Classification of endometrial carcinoma: more than two types. Lancet Oncol. 15:e268–e278. 2014. View Article : Google Scholar : PubMed/NCBI | |
Winterhoff B, Thomaier L, Mullany S and Powell MA: Molecular characterization of endometrial cancer and therapeutic implications. Curr Opin Obstet Gynecol. 32:76–83. 2020. View Article : Google Scholar | |
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer incidence and mortality patterns in Europe Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387. 2018. View Article : Google Scholar : PubMed/NCBI | |
McAlpine JN, Temkin SM and Mackay HJ: Endometrial cancer: Not your grandmother's cancer. Cancer. 122:2787–2798. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hazelwood E, Sanderson E, Tan VY, Ruth KS, Frayling TM, Dimou N, Gunter MJ, Dossus L, Newton C, Ryan N, et al: Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: A mendelian randomization analysis. BMC Med. 20:1252022. View Article : Google Scholar : PubMed/NCBI | |
Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherma ME, Brinton LA, Yu H, Miller DS, et al: Sex hormones, insulin, and insulin-like growth factors in recurrence of high-stage endometrial cancer. Cancer Epidemiol Biomarkers Prev. 30:719–726. 2021. View Article : Google Scholar : PubMed/NCBI | |
Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE and Jaffrey SR: Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell. 149:1635–1646. 2012. View Article : Google Scholar : PubMed/NCBI | |
Huang H, Weng H and Chen J: m6A modification in coding and non-coding RNAs: Roles and therapeutic implications in cancer. Cancer Cell. 37:270–288. 2020. View Article : Google Scholar : PubMed/NCBI | |
Huang H, Weng H and Chen J: The biogenesis and precise control of RNA m6A methylation. Trends Genet. 36:44–52. 2020. View Article : Google Scholar | |
Wang T, Kong S, Tao M and Ju S: The potential role of RNA N6-methyladenosine in cancer progression. Mol Cancer. 19:882020. View Article : Google Scholar : PubMed/NCBI | |
He L, Li H, Wu A, Peng Y, Shu G and Yin G: Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 18:1762019. View Article : Google Scholar : PubMed/NCBI | |
Hu Y, Wang S, Liu J, Huang Y, Gong C, Liu J, Xiao Y and Yang S: New sights in cancer: Component and function of N6-methyladenosine modification. Biomed Pharmacother. 122:1096942020. View Article : Google Scholar : PubMed/NCBI | |
He PC and He C: m6 A RNA methylation: From mechanisms to therapeutic potential. EMBO J. 40:e1059772021. View Article : Google Scholar | |
Lin S, Choe J, Du P, Triboulet R and Gregory RI: The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 62:335–345. 2016. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X, et al: A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 10:93–95. 2014. View Article : Google Scholar : | |
Huang J, Dong X, Gong Z, Qin LY, Yang S, Zhu YL, Wang X, Zhang D, Zou T, Yin P and Tang C: Solution structure of the RNA recognition domain of METTL3-METTL14 N6-methyladenosine methyltransferase. Protein Cell. 10:272–284. 2019. View Article : Google Scholar | |
Ping XL, Sun BF, Wang L, Xiao W, Yang X, Wang WJ, Adhikari S, Shi Y, Lv Y, Chen YS, et al: Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 24:177–189. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yue Y, Liu J, Cui X, Cao J, Luo G, Zhang Z, Cheng T, Gao M, Shu X, Ma H, et al: VIRMA mediates preferential m6A mRNA methylation in 3'UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 4:102018. View Article : Google Scholar | |
Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M and Jaffrey SR: m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 537:369–373. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhu D, Zhou J, Zhao J, Jiang G, Zhang X, Zhang Y and Dong M: ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling. J Cell Physiol. 234:8899–8907. 2019. View Article : Google Scholar | |
Wen J, Lv R, Ma H, Shen H, He C, Wang J, Jiao F, Liu H, Yang P, Tan L, et al: Zc3h13 regulates nuclear RNA m6A methylation and mouse embryonic stem cell self-renewal. Mol Cell. 69:1028–1038.e6. 2018. View Article : Google Scholar | |
Shen D, Wang B, Gao Y, Zhao L, Bi Y, Zhang J, Wang N, Kang H, Pang J, Liu Y, et al: Detailed resume of RNA m6A demethylases. Acta Pharm Sin B. 12:2193–2205. 2022. View Article : Google Scholar : PubMed/NCBI | |
Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG and He C: N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 7:885–887. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wei J, Liu F, Lu Z, Fei Q, Ai Y, He PC, Shi H, Cui X, Su R, Klungland A, et al: Differential m6A, m6Am m, and m1A demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol Cell. 71:973–985.e5. 2018. View Article : Google Scholar | |
Bartosovic M, Molares HC, Gregorova P, Hrossova D, Kudla G and Vanacova S: N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3'-end processing. Nucleic Acids Res. 45:11356–11370. 2017. View Article : Google Scholar : PubMed/NCBI | |
Gao S, Li X, Zhang M, Zhang N, Wang R and Chang J: Structural characteristics of small-molecule inhibitors targeting FTO demethylase. Future Med Chem. 13:1475–1489. 2021. View Article : Google Scholar : PubMed/NCBI | |
Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vågbø CB, Shi Y, Wang WL, Song SH, et al: ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 49:18–29. 2013. View Article : Google Scholar : | |
Qu J, Yan H, Hou Y, Cao W, Liu Y, Zhang E, He J and Cai Z: RNA demethylase ALKBH5 in cancer: From mechanisms to therapeutic potential. J Hematol Oncol. 15:82022. View Article : Google Scholar : PubMed/NCBI | |
Zhao Y, Shi Y, Shen H and Xie W: m6A-binding proteins: The emerging crucial performers in epigenetics. J Hematol Oncol. 13:352020. View Article : Google Scholar | |
Du H, Zhao Y, He J, Zhang Y, Xi H, Liu M, Ma J and Wu L: YTHDF2 destabilizes m(6)A-containing RNA through direct recruitment of the CCR4-NOT deadenylase complex. Nat Commun. 7:126262016. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Gao M, Xu S, Chen Y, Wu K, Liu H, Wang J, Yang X, Wang J, Liu W, et al: YTHDF2/3 are required for somatic reprogramming through different RNA deadenylation pathways. Cell Rep. 32:1081202020. View Article : Google Scholar : PubMed/NCBI | |
Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR and Qian SB: Dynamic m(6)A mRNA methylation directs translational control of heat shock response. Nature. 526:591–594. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H and He C: N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 161:1388–1399. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chen Z, Zhong X, Xia M and Zhong J: The roles and mechanisms of the m6A reader protein YTHDF1 in tumor biology and human diseases. Mol Ther Nucleic Acids. 26:1270–1279. 2021. View Article : Google Scholar : PubMed/NCBI | |
Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C and He C: YTHDF3 facilitates translation and decay of N6-methyladenosine-modified RNA. Cell Res. 27:315–328. 2017. View Article : Google Scholar : PubMed/NCBI | |
Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, Sun HY, Zhu Q, Baidya P, Wang X, et al: Cytoplasmic m6A reader YTHDF3 promotes mRNA translation. Cell Res. 27:444–447. 2017. View Article : Google Scholar : PubMed/NCBI | |
Li S, Qi Y, Yu J, Hao Y, He B, Zhang M, Dai Z, Jiang T, Li S, Huang F, et al: Nuclear Aurora kinase A switches m6A reader YTHDC1 to enhance an oncogenic RNA splicing of tumor suppressor RBM4. Signal Transduct Target Ther. 7:972022. View Article : Google Scholar | |
Kim GW, Imam H and Siddiqui A: The RNA binding proteins YTHDC1 and FMRP regulate the nuclear export of N6-methyladenosine-modified hepatitis B virus transcripts and affect the viral life cycle. J Virol. 95:e00097212021. View Article : Google Scholar | |
Shima H, Matsumoto M, Ishigami Y, Ebina M, Muto A, Sato Y, Kumagai S, Ochiai K, Suzuki T and Igarashi K: S-adenosylmethionine synthesis is regulated by selective N6-adenosine methylation and mRNA degradation involving METTL16 and YTHDC1. Cell Rep. 21:3354–3363. 2017. View Article : Google Scholar : PubMed/NCBI | |
Hsu PJ, Zhu Y, Ma H, Guo Y, Shi X, Liu Y, Qi M, Lu Z, Shi H, Wang J, et al: Ythdc2 is an N6-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 27:1115–1127. 2017. View Article : Google Scholar : PubMed/NCBI | |
Alarcón CR, Goodarzi H, Lee H, Liu X, Tavazoie S and Tavazoie SF: HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events. Cell. 162:1299–1308. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liu N, Dai Q, Zheng G, He C, Parisien M and Pan T: N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 518:560–564. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liu N, Zhou KI, Parisien M, Dai Q, Diatchenko L and Pan T: N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 45:6051–6063. 2017. View Article : Google Scholar : PubMed/NCBI | |
Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, et al: Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 20:285–295. 2018. View Article : Google Scholar : PubMed/NCBI | |
Song K, Xu H and Wang C: The role of N6-methyladenosine methylation in the progression of endometrial cancer. Cancer Biother Radiopharm. Oct 14–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
Lan Q, Liu PY, Haase J, Bell JL, Hüttelmaier S and Liu T: The critical role of RNA m6A methylation in cancer. Cancer Res. 79:1285–1292. 2019. View Article : Google Scholar : PubMed/NCBI | |
Xue T, Liu X, Zhang M, E Q, Liu S, Zou M, Li Y, Ma Z, Han Y, Thompson P and Zhang X: PADI2-catalyzed MEK1 citrullination activates ERK1/2 and promotes IGF2BP1-mediated SOX2 mRNA stability in endometrial cancer. Adv Sci (Weinh). 8:20028312021. View Article : Google Scholar | |
Liu A, Zhang D, Yang X and Song Y: Estrogen receptor alpha activates MAPK signaling pathway to promote the development of endometrial cancer. J Cell Biochem. 120:17593–17601. 2019. View Article : Google Scholar : PubMed/NCBI | |
Barra F, Evangelisti G, Ferro Desideri L, Di Domenico S, Ferraioli D, Vellone VG, De Cian F and Ferrero S: Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs. 28:131–142. 2019. View Article : Google Scholar | |
Wang Y, Yin L and Sun X: CircRNA hsa_circ_0002577 accelerates endometrial cancer progression through activating IGF1R/PI3K/Akt pathway. J Exp Clin Cancer Res. 39:1692020. View Article : Google Scholar : PubMed/NCBI | |
Zhao BS, Roundtree IA and He C: Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 18:31–42. 2017. View Article : Google Scholar | |
Hu C, Liu J, Li Y, Jiang W, Ji D, Liu W and Ma T: Multifaceted roles of the N6-methyladenosine RNA methyltransferase METTL3 in cancer and immune microenvironment. Biomolecules. 12:10422022. View Article : Google Scholar | |
Zheng W, Dong X, Zhao Y, Wang S, Jiang H, Zhang M, Zheng X and Gu M: Multiple functions and mechanisms underlying the role of METTL3 in human cancers. Front Oncol. 9:14032019. View Article : Google Scholar | |
Wei W, Huo B and Shi X: miR-600 inhibits lung cancer via downregulating the expression of METTL3. Cancer Manag Res. 11:1177–1187. 2019. View Article : Google Scholar : PubMed/NCBI | |
Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, et al: The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nat Med. 23:1369–1376. 2017. View Article : Google Scholar : PubMed/NCBI | |
Barbieri I, Tzelepis K, Pandolfini L, Shi J, Millán-Zambrano G, Robson SC, Aspris D, Migliori V, Bannister AJ, Han N, et al: Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature. 552:126–131. 2017. View Article : Google Scholar : PubMed/NCBI | |
Liu T, Yang S, Sui J, Xu SY, Cheng YP, Shen B, Zhang Y, Zhang XM, Yin LH, Pu YP and Liang GY: Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer. J Cell Physiol. 235:548–562. 2020. View Article : Google Scholar | |
Yue B, Song C, Yang L, Cui R, Cheng X, Zhang Z and Zhao G: METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer. Mol Cancer. 18:1422019. View Article : Google Scholar : PubMed/NCBI | |
Hua W, Zhao Y, Jin X, Yu D, He J, Xie D and Duan P: METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol. 151:356–365. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li X, Tang J, Huang W, Wang F, Li P, Qin C, Qin Z, Zou Q, Wei J, Hua L, et al: The M6A methyltransferase METTL3: Acting as a tumor suppressor in renal cell carcinoma. Oncotarget. 8:96103–96116. 2017. View Article : Google Scholar : PubMed/NCBI | |
Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, Liang Y, Zhu F, Zhang Y, Zhang X, et al: The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene. 38:3667–3680. 2019. View Article : Google Scholar : PubMed/NCBI | |
Han J, Wang JZ, Yang X, Yu H, Zhou R, Lu HC, Yuan WB, Lu JC, Zhou ZJ, Lu Q, et al: METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner. Mol Cancer. 18:1102019. View Article : Google Scholar : PubMed/NCBI | |
Zhao S, Liu J, Nanga P, Liu Y, Cicek AE, Knoblauch N, He C, Stephens M and He X: Detailed modeling of positive selection improves detection of cancer driver genes. Nat Commun. 10:33992019. View Article : Google Scholar : PubMed/NCBI | |
Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W and Ye L: HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 415:–19. 2018. View Article : Google Scholar | |
Wu L, Wu D, Ning J, Liu W and Zhang D: Changes of N6-methyladenosine modulators promote breast cancer progression. BMC Cancer. 19:3262019. View Article : Google Scholar : PubMed/NCBI | |
Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, et al: m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 20:1074–1083. 2018. View Article : Google Scholar : PubMed/NCBI | |
Manning BD and Toker A: AKT/PKB signaling: Navigating the network. Cell. 169:381–405. 2017. View Article : Google Scholar : PubMed/NCBI | |
Xue C, Li G, Lu J and Li L: Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression. Signal Transduct Target Ther. 6:4002021. View Article : Google Scholar : PubMed/NCBI | |
Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI | |
Ralser DJ, Condic M, Klümper N, Ellinger J, Staerk C, Egger EK, Kristiansen G, Mustea A and Thiesler T: Comprehensive immunohistochemical analysis of N6-methyladenosine (m6A) writers, erasers, and readers in endometrial cancer. J Cancer Res Clin Oncol. Jun 22–2022.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI | |
Yu HL, Ma XD, Tong JF, Li JQ, Guan XJ and Yang JH: WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells. Onco Targets Ther. 12:6191–6201. 2019. View Article : Google Scholar : PubMed/NCBI | |
Kuai Y, Gong X, Ding L, Li F, Lei L, Gong Y, Liu Q, Tan H, Zhang X, Liu D, et al: Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90. Cell Commun Signal. 16:502018. View Article : Google Scholar : PubMed/NCBI | |
Tang J, Wang F, Cheng G, Si S, Sun X, Han J, Yu H, Zhang W, Lv Q, Wei JF and Yang H: Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability. J Exp Clin Cancer Res. 37:402018. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Peng C, Chen J, Chen D, Yang B, He B, Hu W, Zhang Y, Liu H, Dai L, et al: WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 18:1272019. View Article : Google Scholar : PubMed/NCBI | |
Yu H, Zhao K, Zeng H, Li Z, Chen K, Zhang Z, Li E and Wu Z: N6-methyladenosine (m6A) methyltransferase WTAP accelerates the Warburg effect of gastric cancer through regulating HK2 stability. Biomed Pharmacother. 133:1110752021. View Article : Google Scholar | |
Li Q, Wang C, Dong W, Su Y and Ma Z: WTAP facilitates progression of endometrial cancer via CAV-1/NF-κB axis. Cell Biol Int. 45:1269–1277. 2021. View Article : Google Scholar : PubMed/NCBI | |
Azzam SK, Alsafar H and Sajini AA: FTO m6A demethylase in obesity and cancer: Implications and underlying molecular mechanisms. Int J Mol Sci. 23:38002022. View Article : Google Scholar : PubMed/NCBI | |
Deng X, Su R, Stanford S and Chen J: Critical enzymatic functions of FTO in obesity and cancer. Front Endocrinol (Lausanne). 9:3962018. View Article : Google Scholar | |
Tao L, Mu X, Chen H, Jin D, Zhang R, Zhao Y, Fan J, Cao M and Zhou Z: FTO modifies the m6A level of MALAT and promotes bladder cancer progression. Clin Transl Med. 11:e3102021. View Article : Google Scholar : PubMed/NCBI | |
Su R, Dong L, Li Y, Gao M, Han L, Wunderlich M, Deng X, Li H, Huang Y, Gao L, et al: Targeting FTO suppresses cancer stem cell maintenance and immune evasion. Cancer Cell. 38:79–96.e11. 2020. View Article : Google Scholar : PubMed/NCBI | |
Zhang Z, Zhou D, Lai Y, Liu Y, Tao X, Wang Q, Zhao G, Gu H, Liao H, Zhu Y, et al: Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways. Cancer Lett. 319:89–97. 2012. View Article : Google Scholar : PubMed/NCBI | |
Zhang L, Wan Y, Zhang Z, Jiang Y, Lang J, Cheng W and Zhu L: FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway. RNA Biol. 18:1265–1278. 2021. View Article : Google Scholar : | |
Lewczuk Ł, Pryczynicz A and Guzińska-Ustymowicz K: Cell adhesion molecules in endometrial cancer-a systematic review. Adv Med Sci. 64:423–429. 2019. View Article : Google Scholar : PubMed/NCBI | |
Delaunay S and Frye M: RNA modifications regulating cell fate in cancer. Nat Cell Biol. 21:552–559. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhu Y, Shen J, Gao L and Feng Y: Estrogen promotes fat mass and obesity-associated protein nuclear localization and enhances endometrial cancer cell proliferation via the mTOR signaling pathway. Oncol Rep. 35:2391–2397. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, Chen Y, Sulman EP, Xie K, Bögler O, et al: m6A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 31:591–606.e6. 2017. View Article : Google Scholar | |
Chao Y, Shang J and Ji W: ALKBH5-m6A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia. Biochem Biophys Res Commun. 521:499–506. 2020. View Article : Google Scholar | |
Shen C, Sheng Y, Zhu AC, Robinson S, Jiang X, Dong L, Chen H, Su R, Yin Z, Li W, et al: RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia. Cell Stem Cell. 27:64–80.e9. 2020. View Article : Google Scholar : PubMed/NCBI | |
Thalhammer A, Bencokova Z, Poole R, Loenarz C, Adam J, O'Flaherty L, Schödel J, Mole D, Giaslakiotis K, Schofield CJ, et al: Human AlkB homologue 5 is a nuclear 2-oxoglutarate dependent oxygenase and a direct target of hypoxia-inducible factor 1α (HIF-1α). PLoS One. 6:e162102011. View Article : Google Scholar | |
Zhang C, Samanta D, Lu H, Bullen JW, Zhang H, Chen I, He X and Semenza GL: Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m6A-demethylation of NANOG mRNA. Proc Natl Acad Sci USA. 113:E2047–E2056. 2016. View Article : Google Scholar | |
Guo X, Li K, Jiang W, Hu Y, Xiao W, Huang Y, Feng Y, Pan Q and Wan R: RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner. Mol Cancer. 19:912020. View Article : Google Scholar : PubMed/NCBI | |
Pu X and Gu Z and Gu Z: ALKBH5 regulates IGF1R expression to promote the proliferation and tumorigenicity of endometrial cancer. J Cancer. 11:5612–5622. 2020. View Article : Google Scholar : PubMed/NCBI | |
Chen G, Liu B, Yin S, Li S, Guo Y, Wang M, Wang K and Wan X: Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA. Oncogenesis. 9:812020. View Article : Google Scholar : PubMed/NCBI | |
Li J, Wu L, Pei M and Zhang Y: YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. J Ovarian Res. 13:1112020. View Article : Google Scholar : PubMed/NCBI | |
Xu F, Li J, Ni M, Cheng J, Zhao H, Wang S, Zhou X and Wu X: FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2. Mol Cancer. 20:452021. View Article : Google Scholar | |
Li Z, Luo Q, Wang H, Liu Y, Feng X, Li Z and Yi P: Knockdown of YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) inhibits cell proliferation and promotes apoptosis in cervical cancer cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 36:255–263. 2020.In Chinese. PubMed/NCBI | |
Shen X, Zhao K, Xu L, Cheng G, Zhu J, Gan L, Wu Y and Zhuang Z: YTHDF2 inhibits gastric cancer cell growth by regulating FOXC2 signaling pathway. Front Genet. 11:5920422021. View Article : Google Scholar : PubMed/NCBI | |
Zhong L, Liao D, Zhang M, Zeng C, Li X, Zhang R, Ma H and Kang T: YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer Lett. 442:252–261. 2019. View Article : Google Scholar | |
Hong L, Pu X, Gan H, Weng L and Zheng Q: YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A. J Cancer. 12:3809–3818. 2021. View Article : Google Scholar : | |
Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M and Levitzki A: Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 73:4383–4394. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ganeff C, Chatel G, Munaut C, Frankenne F, Foidart JM and Winkler R: The IGF system in in-vitro human decidualization. Mol Hum Reprod. 15:27–38. 2009. View Article : Google Scholar | |
Hopkins BD, Goncalves MD and Cantley LC: Insulin-PI3K signalling: An evolutionarily insulated metabolic driver of cancer. Nat Rev Endocrinol. 16:276–283. 2020. View Article : Google Scholar : PubMed/NCBI | |
Shen J, Feng XP, Hu RB, Wang H, Wang YL, Qian JH and Zhou YX: N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma. Lab Invest. 101:775–784. 2021. View Article : Google Scholar : PubMed/NCBI | |
Luo L, Zhen Y, Peng D, Wei C, Zhang X, Liu X, Han L and Zhang Z: The role of N6-methyladenosine-modified non-coding RNAs in the pathological process of human cancer. Cell Death Discov. 8:3252022. View Article : Google Scholar : PubMed/NCBI | |
Li Y, Zhang W, Liu P, Xu Y, Tang L, Chen W and Guan X: Long non-coding RNA FENDRR inhibits cell proliferation and is associated with good prognosis in breast cancer. Onco Targets Ther. 11:1403–1412. 2018. View Article : Google Scholar : PubMed/NCBI | |
Liu J and Du W: LncRNA FENDRR attenuates colon cancer progression by repression of SOX4 protein. Onco Targets Ther. 12:4287–4295. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhang YQ, Chen X, Fu CL, Zhang W, Zhang DL, Pang C, Liu M and Wang JY: FENDRR reduces tumor invasiveness in prostate cancer PC-3 cells by targeting CSNK1E. Eur Rev Med Pharmacol Sci. 23:7327–7337. 2019.PubMed/NCBI | |
Bian PP, Liu SY, Luo QP and Xiong ZT: YTHDF2 is a novel diagnostic marker of endometrial adenocarcinoma and endometrial atypical hyperplasia/intraepithelial neoplasia. Pathol Res Pract. 234:1539192022. View Article : Google Scholar | |
Müller S, Bley N, Glaß M, Busch B, Rousseau V, Misiak D, Fuchs T, Lederer M and Hüttelmaier S: IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors. Nucleic Acids Res. 46:6285–6303. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sun CY, Cao D, Du BB, Chen CW and Liu D: The role of Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) as m6A readers in cancer. Int J Biol Sci. 18:2744–2758. 2022. View Article : Google Scholar : | |
Ma J, Yang D and Ma XX: Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer. Aging (Albany NY). 13:16287–16315. 2021. View Article : Google Scholar | |
Zhang L, Wan Y, Zhang Z, Jiang Y, Gu Z, Ma X, Nie S, Yang J, Lang J, Cheng W and Zhu L: IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression. Theranostics. 11:1100–1114. 2021. View Article : Google Scholar : PubMed/NCBI | |
Nicholson AL and Pasquinelli AE: Tales of detailed poly(A) tails. Trends Cell Biol. 29:191–200. 2019. View Article : Google Scholar | |
Xie T, Pan S, Zheng H, Luo Z, Tembo KM, Jamal M, Yu Z, Yu Y, Xia J, Yin Q, et al: PEG10 as an oncogene: Expression regulatory mechanisms and role in tumor progression. Cancer Cell Int. 18:1122018. View Article : Google Scholar : PubMed/NCBI | |
Peng YP, Zhu Y, Yin LD, Zhang JJ, Wei JS, Liu X, Liu XC, Gao WT, Jiang KR and Miao Y: PEG10 overexpression induced by E2F-1 promotes cell proliferation, migration, and invasion in pancreatic cancer. J Exp Clin Cancer Res. 36:302017. View Article : Google Scholar : PubMed/NCBI | |
Li Y, Guo D, Lu G, Mohiuddin Chowdhury ATM, Zhang D, Ren M, Chen Y, Wang R and He S: LncRNA SNAI3-AS1 promotes PEG10-mediated proliferation and metastasis via decoying of miR-27a-3p and miR-34a-5p in hepatocellular carcinoma. Cell Death Dis. 11:6852020. View Article : Google Scholar : PubMed/NCBI | |
Kawai Y, Imada K, Akamatsu S, Zhang F, Seiler R, Hayashi T, Leong J, Beraldi E, Saxena N, Kretschmer A, et al: Paternally expressed gene 10 (PEG10) promotes growth, invasion, and survival of bladder cancer. Mol Cancer Ther. 19:2210–2220. 2020. View Article : Google Scholar : PubMed/NCBI | |
Chang X, Han J, Pang L, Zhao Y, Yang Y and Shen Z: Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer. 9:402009. View Article : Google Scholar : PubMed/NCBI | |
Pang X, Zhang X, Huang Y and Qian S: Development and validation of m6A regulators' prognostic significance for endometrial cancer. Medicine (Baltimore). 100:e265512021. View Article : Google Scholar | |
Wang Y, Ren F, Song Z, Wang X and Ma X: Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma. J Cancer. 11:6390–6401. 2020. View Article : Google Scholar : PubMed/NCBI | |
Han Y, Liu D and Li L: PD-1/PD-L1 pathway: Current researches in cancer. Am J Cancer Res. 10:727–742. 2020.PubMed/NCBI | |
Zhai J, Li S, Li Y and Du Y: Data mining analysis of the prognostic impact of N6-methyladenosine regulators in patients with endometrial adenocarcinoma. J Cancer. 12:4729–4738. 2021. View Article : Google Scholar : | |
Huisman B, Manske G, Carney S and Kalantry S: Functional dissection of the m6A RNA modification. Trends Biochem Sci. 42:85–86. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yang Y, Hsu PJ, Chen YS and Yang YG: Dynamic transcriptomic m6A decoration: Writers, erasers, readers and functions in RNA metabolism. Cell Res. 28:616–624. 2018. View Article : Google Scholar : PubMed/NCBI | |
Xu Z, Peng B, Cai Y, Wu G, Huang J, Gao M, Guo G, Zeng S, Gong Z and Yan Y: N6-methyladenosine RNA modification in cancer therapeutic resistance: Current status and perspectives. Biochem Pharmacol. 182:1142582020. View Article : Google Scholar : PubMed/NCBI | |
Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y, Weng X, Hu C, et al: R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling. Cell. 172:90–105.e23. 2018. View Article : Google Scholar | |
Zhang J, Tsoi H, Li X, Wang H, Gao J, Wang K, Go MY, Ng SC, Chan FK, Sung JJ and Yu J: Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP-WT1-TBL1 axis. Gut. 65:1482–1493. 2016. View Article : Google Scholar |